A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Manon DurandVincent Cabaud GibouinLaurence DuplombLeila SalmiMélody CaillotBrigitte SolaVincent CamusFabrice JardinCarmen GarridoGaëtan JegoPublished in: Journal of experimental & clinical cancer research : CR (2024)
These findings suggest that HSP110 could be proposed as a novel target in PMBL and cHL therapy.